Anxiety Disorder and Its Management In Patients With Cardiovascular Disease

Ruge, M. E. Assessment and management of the anxious patient in the cardiac catheter laboratory Thesis, Australian Catholic University. (2013). Doi: 10.4226/66/5a9750313ba9b

Stein DJ, Scott KM, De Jonge P, et al Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues in Clinical Neuroscience (2017)Doi: 10.31887/DCNS.2017.19.2/dstein

Celano CM, Daunis DJ, Lokko HN, et al Anxiety Disorders and Cardiovascular Disease. Current Psychiatry Reports. 2016. doi: 10.1007/s11920-016-0739-5

4-American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.

Tully PJ, Cosh SM. Generalized anxiety disorder prevalence and comorbidity with depression in coronary heart disease: a meta-analysis. Journal of health psychology vol. 18,.(2013); doi: 10.1177/1359105312467390.

Roest AM, Zuidersma M, De Jonge P. Myocardial infarction and generalised anxiety disorder: 10- year follow-up. The British journal of psychiatry : the journal of mental science vol. 2004 (2012) doi:10.1192/bjp.bp.111.103549.

Tully PJ, Winefield HR, Baker RA, et al. Depression, anxiety and major adverse cardiovascular and cerebrovascular events in patients following coronary artery bypass graft surgery: a five year longitudinal cohort study. Biopsychosocial Medicine.(2015) doi:10.1186/s13030-015-0041-5

Todaro JF, Shen BJ, Raffa SD, et al. Prevalence of anxiety disorders in men and women with established coronary heart disease. Journal of cardiopulmonary rehabilitation and prevention vol. 27,2(2017). doi:10.1097/01.HCR.0000265036.24157.e7

Huffman JC, Pollack MH. Predicting panic disorder among patients with chest pain: an analysis of the literature. Psychosomatics. 2003; doi:10.1176/appi.psy.44.3.222

Tully PJ, Turnbull DA, Beltrame J, et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychological medicine vol. 45,14 (2015); doi:10.1017/S0033291715000963.

Ahmadi N, Hajsadeghi F, Mirshkarlo HB, et al. Post-traumatic stress disorder, coronary atherosclerosis, and mortality. The American journal of cardiology (2011) . doi:10.1016/ j.amjcard.2011.02.34.

Roy SS, Foraker RE, Girton RA, et al. Posttraumatic stress disorder and incident heart failure among a community-based sample of US veterans. American journal of public health vol. 105,4. 2015; doi:10.2105/AJPH.2014.302342.

Hu MX, Lamers F, de Geus EJ, et al.. Differential Autonomic Nervous System Reactivity in Depression and Anxiety During Stress Depending on Type of Stressor. Psychosom Med. 2016;78(5):562-572. doi:10.1097/PSY.0000000000000313

Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001 doi: 10.2337/diacare.24.10.1793

Roerink, M. E., Groenewold, N. A., Franssen, et al Anxiety, depression, and autonomic nervous system activity: A review of the evidence and implications for health and disease. Neuroscience & Biobehavioral Reviews,(2017). doi: 10.1016/j.neubiorev.2017.08.011

Ridker, P. M., Everett, B. M., Thuren, et al Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, (2017). doi: 10.1056/NEJMoa1707914

Pitsavos C, Panagiotakos DB, Papageorgiou C, et al. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis. 2006; doi:10.1016/j.atherosclerosis.2005.06.001.

Ross R. Atherosclerosis--an inflammatory disease. The New England journal of medicine vol. 340,21999; doi: 10.1056/NEJM199901143400207.

Moyer CF, Sajuthi D, Tulli H, et al. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis..” The American journal of pathology vol. 138,4 (19911991; [PubMed: 2012178]

Hohensinner PJ, Niessner A, Huber K, et al. Inflammation and cardiac outcome. Current opinion in infectious diseases vol. 24,3 2011; doi:10.1097/QCO.0b013e328344f50f.

Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; Doi: 10.1161/hc4601.099485

Drexler H. Endothelial dysfunction: clinical implications. Progress in cardiovascular diseases vol. 39,4 1997; 39(4):287– 324. doi:S0033-0620(97)80030-8

Narita K, Murata T, Hamada T, et al. Interactions among higher trait anxiety, sympathetic activity, and endothelial function in the elderly. Journal of psychiatric research vol. 41,5. 2007; doi:10.1016/j.jpsychires.2006.01.003

Vorchheimer DA,Becker R . "Platelets in atherothrombosis." Mayo Clinic Proceedings. Vol. 81. No. 1. Elsevier, 2006.DOI:https://doi.org/10.4065/81.1.59

Garvey MJ, Noyes R, Woodman C, et al. The association of urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid in patients with generalized anxiety. Neuropsychobiology. 1995; Doi: 10.1159/000119165

Neumeister A, Bain E, Nugent AC,, et al. Reduced serotonin type 1A receptor binding in panic disorder. The Journal of neuroscience : the official journal of the Society for Neuroscience vol. 24,3. 2004; doi: 10.1523/JNEUROSCI.4921-03.2004

Miyata K, Shimokawa H, Higo T,, et al. Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. Journal Of Cardiovascular Pharmacology 2000; 35(2):294–301. [PubMed: 10672864]

Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999; Doi:doi:10.1161/01.cir.100.5.483

Roohafza, H. R., Afshar, H., Keshteli, A. H., et al What's the role of perceived social support and coping styles in depression and anxiety?. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences,(2016). pmıd: 25538777; pmcıd: pmc4274570.

Kuhl EA, Fauerbach JA, Bush DE, et al. Relation of anxiety and adherence to risk- reducing recommendations following myocardial infarction. The American journal of cardiology vol. 103,12. 2009; doi:10.1016/j.amjcard.2009.02.014

Roest, A. M., Martens, E. J., de Jonge, P., et al(2010). Anxiety and risk of incident coronary heart disease: a meta-analysis. Journal of the American College of Cardiology,(2010).doi:10.1016/j.jacc.2010.03.034

Alvarez W, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy. (2003)doi:10.1592/phco.23.6.754.32185

Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;.doi:10.1001/jama.288.6.701

Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007doi:10.1001/jama.297.4.367

Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine 2000; 62(6): 783–9. [PubMed: 11138997]

Fraguas R, Da Silva Telles RM, Alves TC, et al. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. Contemporary clinical trials vol. 30,3 2009; doi:10.1016/j.cct.2009.01.007

Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. American Heart Journal vol. 153,5 2007;.doi:10.1016/j.ahj.2007.02.024

O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. Journal of the American College of Cardiology vol. 56,9. 2010; doi:10.1016/j.jacc.2010.03.068

Pellicori P, Clark AL. Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure. European journal of heart failure vol. 17,9 2015;. doi:10.1002/ejhf.340.

Angermann CE, Gelbrich G, Stork S, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re- uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD- HF). European journal of heart failure vol. 9,12. 2007; doi:10.1016/j.ejheart.2007.10.005

Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. The Journal of clinical psychiatry vol. 75,5. 2014; doi:10.4088/JCP.13r08672.

Beach SR, Celano CM, Noseworthy P, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013; doi:10.1016/j.psym.2012.11.001

Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ (Clinical research ed.). 2013;. doi: 10.1136/bmj.f288

Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? The American journal of medicine vol. 119,2. 2006; doi:10.1016/j.amjmed.2005.03.044

Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 doi:10.1161/01.CIR.0000085163.21752.0A

Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006 doi:63/12/1358 [pii] 10.1001/archpsyc.63.12.1358.

Kimmel SE, Schelleman H, Berlin JA, et al. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. British journal of clinical pharmacology vol. 72,3. 2011; doi:10.1111/j. 1365-2125.2011.04008.x.

Batista M, Dugernier T, Simon M, et al. The spectrum of acute heart failure after venlafaxine overdose. Clinical toxicology (Philadelphia, Pa.) vol. 51,2). 2013; doi: 10.3109/15563650.2012.763133.

Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Annals of Pharmacotherapy. 2008; doi:10.1345/aph.1L031

Huffman JC, Stern TA. The use of benzodiazepines in the treatment of chest pain: a review of the literature. Journal of emergency medicine vol. 25,4. 2003;.doi:10.1016/j.jemermed.2003.01.001

Wu CK, Huang YT, Lee JK, et al. Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction: a national wide assessment. Atherosclerosis. 2014; doi:10.1016/j.atherosclerosis.2014.05.918

Zaal IJ, Devlin JW, Hazelbag M, , et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Medicine. 2015 doi:10.1007/s00134-015-4063-z

Serafim RB, Dutra MF, Saddy F, et al. Delirium in postoperative nonventilated intensive care patients: risk factors and outcomes. Annals of Intensive Care. 2012; doi:10.1186/2110-5820-2-51

de Jong MR, Van der Elst M, Hartholt KA. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Therapeutic advances in drug safety vol. 4,4 2013; doi:10.1177/2042098613486829

Tully PJ, Selkow T, Bengel J,et al.. A dynamic view of comorbid depression and generalized anxiety disorder symptom change in chronic heart failure: the discrete effects of cognitive behavioral therapy, exercise, and psychotropic medication. Disability and rehabilitation vol. 37,72015; doi:10.3109/09638288.2014.935493